M. Combe

发表

Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial.

B. Weber, E. Pujade-Lauraine, A. Lortholary, 2009, Anticancer research.

HER2 Overexpression/Amplification and Trastuzumab Treatment in Advanced Ovarian Cancer: A GINECO Phase II Study

B. Weber, I. Ray-Coquard, E. Pujade-Lauraine, 2008 .

Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial.

B. Weber, F. Mayer, J. Ferrero, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients

Philippe Broët, Anne Vincent-Salomon, Jérôme Couturier, 2007, PloS one.

Final results of the RAPP-01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high-risk node negative and limited node positive (≤3) breast cancer patients.

T. Bachelot, M. Debled, E. Fourme, 2009 .

Sequential or simultaneous chemo-radiotherapy in operable breast cancer. A French multicentric phase III study — State of inclusions

L. Demange, C. Noguès, D. Serin, 1998 .

Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer.

T. Bachelot, E. Brain, C. Noguès, 2005, JAMA.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

P. Couzigou, M. Ducreux, C. Borel, 2018, European journal of cancer.

Carboplatin (PA) and pegylated liposomal doxorubicin (CA; PACA regimen) in patients with advanced ovarian cancer in late (>6 months) relapse (AOCLR): Survival results of a GINECO phase II trial

B. Weber, F. Mayer, J. Ferrero, 2004 .

Original article DOI: 10.1093/annonc/mdg449 Phase

P. Fumoleau, V. Diéras, T. Bachelot, 2022 .

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.

L. Demange, E. Mouret‐Fourme, C. Noguès, 2006, International journal of radiation oncology, biology, physics.

Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high-risk node negative (pN0) and limited node positive (pN+≤3) breast cancer (BC) patients (pts): First analysis of toxicity

T. Bachelot, E. Brain, C. Noguès, 2004 .

HER2 overexpression and amplification in advanced ovarian cancer (AOC): Treatment with trastuzumab—A GINECO study

B. Weber, E. Pujade-Lauraine, H. Curé, 2007 .

Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIB-IV. An AGO-GINECO Intergroup phase III trial.

B. Weber, S. Loibl, C. Jackisch, 2004, Journal of Clinical Oncology.

Long Term Persistent Alopecia and Suboptimal Hair Regrowth after Adjuvant Chemotherapy for Breast Cancer: Alert for an Emerging Side Effect: ALOPERS Observatory.

F. Denis, P. Kerbrat, J. Metges, 2009 .

Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer.

P. Fumoleau, V. Diéras, T. Bachelot, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[Palpable mantel cell lymphoma in the breast].

P. Renou, M. Coulon, J. Dugay, 2001, Presse medicale.